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Abstract Testosterone (T) levels are decreased in obese
men, but the underlying causes are incompletely under-
stood. Our objective was to explore the relation between
low (free) T levels and male obesity, by evaluating
metabolic parameters, subcutaneous adipose tissue (SAT)
aromatase expression, and parameters of the hypotha-
lamic–pituitary–gonadal axis. We recruited 57 morbidly
obese men [33 had type 2 diabetes (DM2)] and 25 normal-
weight men undergoing abdominal surgery. Fourteen obese
men also attended a follow-up, 2 years after gastric bypass
surgery (GBS). Circulating T levels were quantified by
LC–MS/MS, whereas free T levels were measured using
serum equilibrium dialysis and sex hormone-binding glo-
bulin, luteinizing hormone, and follicle-stimulating hor-
mone by immunoassay. SAT biopsies were used to
determine adipocyte cell size and aromatase expression by
real-time PCR. Total and free T levels were decreased in
obese males versus controls, with a further decrease in
obese men with DM2 versus obese men without DM2.
There were no differences in aromatase expression among
the study groups, and sex steroids did not correlate with
aromatase expression. Pearson analysis revealed an inverse
association between (free) T and SAT cell size, triglyc-
erides, and HOMA-IR. Multivariate analysis confirmed the
inverse association between (free) T and SAT cell size
(b = -0.321, P = 0.037 and b = -0.441, P = 0.011,
respectively), independent of age, triglycerides, HOMA-
IR, obesity, or diabetes. T levels were normalized 2 years
after GBS. These data suggest that SAT cell size rather
than SAT aromatase expression or parameters of the hy-
pothalamic–pituitary–gonadal axis is related to low T in
male obesity, which points to adipose cell size-related
metabolic changes as a major trigger in decreased T levels.
Keywords Aromatase  Adipocyte cell size  Obesity 
Type 2 diabetes
Introduction
The relationship between decreased testosterone (T) levels
and male obesity is incompletely understood. In general,
the synthesis of T by Leydig cells in the testis is stimulated
by luteinizing hormone (LH) together with follicle-
stimulating hormone (FSH). Estradiol (E2) is known to be
an important down-regulator of serum T levels by in-
hibiting the release of these gonadotropins from the pitu-
itary gland [1, 2]. Some studies suggest that an increased
activity of aromatase, the enzyme converting T into E2, in
adipose tissue may contribute to elevated E2 levels in obese
men [3, 4]. However, data on E2 levels in obese men are
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inconsistent, as some studies reported increased E2 levels,
while others reported no changes or even lower levels [5–
7]. Alternatively, abdominal obesity itself may contribute
to the decline in circulating T levels [8, 9]. Obesity leads to
an expansion of fat (hypertrophy of adipocytes), which is
associated with a deteriorated metabolic profile, including
glucose intolerance, dyslipidemia, hypertension, and in-
flammation [10, 11]. Prospective studies have shown that
both adiposity and the presence of the metabolic syndrome
are predictive of future low T levels and could accelerate
the age-related decline of T [12, 13]. Consistently, weight
loss has led to increased T levels in obese men [14, 15].
Although the underlying mechanisms are still unclear,
these findings suggest that hypertrophy of the adipocytes
and its related metabolic changes may associate with the
decline in T levels in obese men.
This cross-sectional study aimed to explore potential
determinants of (free) T levels in a cohort of morbidly
obese men with and without type 2 diabetes as well as men
with normal body weight. Specifically, associations with
adipose tissue aromatase expression levels, subcutaneous
adipose tissue (SAT) cell size, and insulin resistance and
triglyceride (TG) levels (marker of adiposity) were exam-
ined. Furthermore, the effects of weight loss following
gastric bypass surgery (GBS) on (free) T levels and po-
tential determinants thereof were examined in morbidly
obese men at a follow-up examination 2 years after GBS.
Research design and methods
Subjects
The study cohort consisted of twenty-five normal-weight
and fifty-seven morbidly obese men. Thirty-three of the
morbidly obese men had type 2 diabetes according to the
American Diabetes Association (ADA) criteria [16]. All
men were scheduled for abdominal surgery. The obese men
underwent GBS, and normal-weight men had surgery for
adhesiolysis, rupture of the stomach, intestinal resection,
stomach closing, or Nissen fundoplication. Obesity was
defined as BMI [30 kg/m2. Although having abdominal
surgery, the normal-weight men had an overall good
health. Participants with primary hypogonadism, abnormal
thyroid function, hepatitis or malignancies, serum total
cholesterol [300 mg/dl, and/or serum TG [450 mg/dl
were excluded. None of the subjects used steroids, and oral
glucose-lowering medication were discontinued prior to
surgery. A subgroup of thirty-six patients that underwent
GBS was invited for a follow-up examination, when
2 years had passed since surgery. Fourteen of them were
willing to participate (39 %). Subjects attending follow-up
were not using sex steroids or other androgen-related
drugs, and three out of fourteen subjects were using met-
formin medication. The study was approved by the insti-
tutional ethics committee, and participants gave their
written informed consent, which was validated by the
Ethical Review Board of Ghent University Hospital and
conducted according to the principles of the Declaration of
Helsinki (Registration no: B67020084018).
At baseline and during follow-up, clinical and anthro-
pometric parameters were assessed as described previously
[17]. The fat percentage of body weight (fat %) was esti-
mated by bio-impedance (Bodystat 1500, Bodystat, Ltd,
Isle of Man, UK).
Hormonal and biochemical assays
Blood samples were collected from the patients after
overnight fasting, prior to surgery. Serum samples were
centrifuged, fractionated, and stored at -80 C until ana-
lysis. Fasting TG, glucose, and insulin levels were mea-
sured using standard laboratory assays (modular
immunoassay, Roche Diagnostics, Mannheim, Germany).
HOMA-IR was calculated with the following formula:
(fasting glucose [mmol/L] 9 fasting insulin [lU/mL])/
22.5] [18]. Total T and E2 were measured with liquid
chromatography tandem mass spectrometry (LC–MS/MS).
Serum T levels were analyzed using a Waters C-18 acquity
ultra-performance liquid chromatography (UPLC) column
(Waters Corporation, Milford, MA, USA), with a limit of
quantification (LOQ) of 0.087 nmol/L (CV\20 %, n C 6).
Intra- and inter-assay coefficients of variation (CV) were
9.1 % at 0.48 nmol/L and 7.3 % at 1.35 nmol/L, respec-
tively. For determination of E2 levels, 2D-LC–MS/MS was
performed on an AB Sciex 5500 triple-quadrupole mass
spectrometer (AB Sciex, Toronto, Canada) as described by
Fiers et al. [19]. LOQ (CV \20 %, n C 6) could be
ascertained at 1.1 pmol/L for E2, and intra- and inter-assay
CV were 3.7 % at 69.4 pmol/L and 4.0 % at 77.4 pmol/L,
respectively. Free T levels were measured using a validated
equilibrium dialysis method, as described previously by
Vermeulen et al. [20]. Free E2 levels were calculated from
total E2, sex hormone-binding globulin (SHBG), and al-
bumin concentrations as described elsewhere [21]. Com-
mercial immunoassays were used to determine SHBG
(Orion Diagnostica, Espoo, Finland), LH, and FSH (Elec-
sys LH and FSH immunoassay; Roche Diagnostics).
Adipose tissue processing
SAT biopsies were obtained at the end of the surgical in-
tervention and stored at -80 C until further analysis, or
fixated in formol (buffered 4 % paraformaldehyde solution;
Klinipath, Belgium) at room temperature for microscopic
analysis. Fixation, dehydration, cleaning, and paraffin
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impregnation (Tissue Tek Vip, Sakura, USA) of these
samples were performed, followed by embedding with a
TBS 88 Paraffin Embedding System (Medite, USA). By
means of a Tissue Tek Prisma (Sakura), Hematoxylin–eosin
staining and film coverslipping of 3 lm slides were com-
pleted. Digital photographs of the paraffin slides were taken
with an AxioCam ERc 5s camera and Axioskop 20 light
microscope (Zeiss, Jena, Germany) at 920 magnification,
with a total of 6 photographs per slide (Fig. 1). The surface
area of by average 143 adipocytes per slide was then
measured using the ZEN 2011 software (Zeiss) by indi-
cating the margins of the cell membrane of all complete
adipocytes. As adipocytes were assumed to be spheres, as
many as possible complete imaged adipocytes were mea-
sured in order to calculate the median surface area as ex-
pressed in lm2 per study patient, followed by calculation of
the median SAT cell size per study group. SAT cell size
assessment was blinded to grouping and was determined in
50 subjects from the cross-sectional study cohort.
Aromatase expression was determined in the frozen
SAT samples of 36 subjects using real-time polymerase
chain reaction (real-time PCR). First, RNA was isolated
out of 100 mg of the frozen fat biopsies with the Tripure
Isolation Reagent kit (Roche Diagnostics) according to the
manufacturer’s instructions. Contaminating genomic DNA
was removed with the RNase-Free DNase Set (Qiagen,
Hilden, Germany), followed by a clean-up step with the
RNeasy Mini Kit (Qiagen). cDNA synthesis was carried
out using the SuperScript First-Strand Synthesis System for
RT-PCR kit (Invitrogen, Ghent, Belgium) according to the
manufacturer’s instructions. Aromatase expression levels
were quantified by real-time PCR using a Quantitect
CYP19A1 primer assay (Qiagen) and SYBR Green PCR
Master Mix (Applied Biosystems, Foster City, CA, USA)
on a StepOne Plus system (Applied Biosystems). The
obtained threshold cycle (Ct) values were normalized for
the expression of the stable reference gene RPS18 (Quan-
titect RPS18 primer assay; Qiagen) using the DCt-method.
Statistical analysis
The statistical analysis was performed using IBM SPSS
Statistics (version 20.0). Data distribution was evaluated
with the Kolmogorov–Smirnov test. Variables displaying a
normal distribution were expressed as mean ± SD,
whereas non-Gaussian distributed variables were described
as median (interquartile range). ANOVA and Tukey HSD
post hoc test were used for the comparison of variables
among non-obese men, morbidly obese men, and morbidly
obese men with type 2 diabetes of the cross-sectional study.
Non-Gaussian distributed variables were tested using
Kruskal–Wallis and Mann–Whitney U test. Pearson cor-
relation coefficients were calculated for the whole study
samples as well as for the subgroups (normal-weight men
and obese men with and without type 2 diabetes) and were
adjusted for age. If not normally distributed, the variables
underwent a logarithmic transformation prior to analysis.
Multivariate linear regression analysis was used to identify
independent factors associated with T levels in men, using
a model containing significant variables from univariate
analysis. Regression analysis was corrected for grouping
by adding obesity and type 2 diabetes as independent bi-
nary variables (yes/no) to the model. Prior to regression
analysis, variables were standardized in order to retrieve
standard error (SE) and 95 % confidence intervals (95 %
CI) on b coefficients. Effects after bariatric surgery were
analyzed using a paired student t test or Wilcoxon mat-
ched-pairs signed-ranks test in case of non-parametric data
distribution. P values \0.05 (two-tailed) were considered
statistically significant.
Fig. 1 Digital photographs of the subcutaneous adipose tissue (SAT)
paraffin slides from a control and obese subject without and with type
2 diabetes, respectively. Photographs were taken with an AxioCam
ERc 5s camera placed on an Axioskop 20 light microscope at 920
magnification. Mean surface area of adipocytes was measured using
the ZEN 2011 software by indicating margins of all complete
adipocytes imaged on the slides, expressed in lm2. Presented images
were randomly selected. Scale bar represents 100 lm
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Results
Subject characteristics
Characteristics of the study participants are listed in Table 1.
Briefly, obese men without type 2 diabetes were younger as
compared to the normal-weight men and obese men with
type 2 diabetes (41 [32–49] versus 49 [43–64] versus 54
[50–61] years, respectively; (median[Q1–Q3]) P = 0.001).
Apart from a higher BMI, the obese men were insulin re-
sistant and had an increased fasting glucose, fasting insulin,
and fasting TG levels versus normal-weight men. In obese
men with type 2 diabetes, BMI, HOMA-IR, and fasting in-
sulin as well as fasting glucose levels were even higher as
compared to obese men without type 2 diabetes. Finally,
although SAT cell size was similar between obese men with
and without type 2 diabetes, it almost doubled versus normal-
weight men (Table 1).
Obese men with type 2 diabetes had lowest T levels
versus obese men without type 2 diabetes and normal-
weight men, respectively (7.17, 10.81, and 16.36 nmol/L,
respectively; P\ 0.001). Similarly, free T levels were
lowest in obese men with type 2 diabetes versus obese men
without type 2 diabetes and normal-weight men, respec-
tively (164.1, 239.5, and 295.0 pmol/L, respectively;
P\ 0.001). There were no differences in circulating E2
levels and SAT aromatase expression among the groups.
Finally, levels of FSH and SHBG were 35 and 43 % lower
in obese men, respectively, irrespective of type 2 diabetes,
whereas LH levels were similar among the groups
(Table 1).
Associations with testosterone levels
To identify potential mechanisms underlying the decrease
in circulating (free) T levels in obese men, we performed a
univariate correlation analysis. SAT aromatase expression
showed no associations with sex steroids or with metabolic
parameters neither in the whole study sample nor when
analyzing subgroups (latter data not shown). In contrast, T
was strongly negative associated with TG levels (r =
-0.390, P\ 0.001), HOMA-IR (r = -0.444, P\ 0.001),
and SAT cell size (r = -0.619, P\ 0.001), in the whole
study cohort. Similarly, free T levels were also negatively
associated with TG levels (r = -0.242, P = 0.033),
HOMA-IR (r = -0.286, P = 0.013), and SAT cell size
(r = -0.599, P\ 0.001) (Table 2). All correlation ana-
lyses were adjusted for age. An additional BMI adjustment
retained the inverse association between T levels and TG
levels (r = -0.235, P = 0.041), as well as between free T
levels and SAT cell size (r = -0.340, P = 0.020). Fur-
thermore, subgroup analyses revealed that the inverse
correlation between total T levels and TG (r = -0.506,
P = 0.016), as well as between free T levels and SAT cell
size (r = -0.719, P = 0.019) (Fig. 2), remained sig-
nificant in obese men without type 2 diabetes. Finally,
when T-to-E2 ratio (ratio T/E2) was considered, similar
results were found. Apart from the obvious relations to E2,
ratio T/E2 was negatively associated with TG (r = -0.388,
P\ 0.001), HOMA-IR (r = -0.606, P\ 0.001), and
SAT cell size (r = -0.648, P\ 0.001). Furthermore, there
was a negative association with SAT aromatase, though
this association was less strong (r = -0.343; P = 0.047)
(Table 2).
To further substantiate the above findings, multivariate
linear regression analysis was applied. Parameters showing
statistical significance in univariate analysis were entered
as variables of interest, after controlling for age and
grouping (control versus obesity/diabetes). Regression
analysis confirmed associations between T levels and SAT
cell size (b = -0.324, P = 0.040) in a model which
contained age, grouping, TG levels, and HOMA-IR. An
identical model with free T levels and T/E2 ratio (the latter
model contained also SAT aromatase considering its sta-
tistical significance in univariate analysis) as dependent
variable showed similar results (b = -0.446, P = 0.013
and b = -0.391, P = 0.051, respectively) (Table 3).
Characteristics and sex steroid levels of study
participants after GBS
Fourteen men agreed to undergo a follow-up investigation
2 years after GBS. Table 4 displays their characteristics
and sex steroid levels at baseline and 2 years after GBS.
Metabolic characteristics of subjects who participated in
the prospective study changed with a significant improve-
ment of BMI (45–34 kg/m2), fat mass (45–36 %), TG
(borderline; 1.55–1.09 mmol/L), glucose (6.47–5.35
mmol/L) and insulin (122.0–61.1 pmol/L) concentrations,
and insulin sensitivity (HOMA-IR 3.3–1.1). Mean total T
levels increased from 8.99 to 14.62 nmol/L (P = 0.004),
SHBG levels increased from 27.9 to 52.4 nmol/L
(P\ 0.001), and FSH levels increased from 5.7 to 7.4 IU/
L (P\ 0.001). No significant differences could be estab-
lished for free T or E2 before and after bariatric surgery.
There were no associations of D (free) T levels with any of
the improved parameters (latter data not shown).
Discussion
The present study showed a link between enlarged SAT
cell size and low T levels in male obesity and could not
establish a predominant role for adipose tissue aromatase
expression and parameters of the hypothalamic–pituitary–
gonadal (HPG) axis. SAT cell size was independently
Endocrine (2015) 50:202–211 205
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inversely associated with both total and free T levels after
multivariate regression analysis corrected for age, grouping
(control versus obesity/diabetes), HOMA-IR, and TG
levels. Overall, the findings suggest that low T in male
obesity might be related to enlargement of SAT cell size
and its related metabolic changes.
In response to an ongoing energy supply, adipose tissue
is known to expand, due to enlargement of adipocytes [22].
Previous hypotheses suggested that low T levels in obese
men may result from an up-regulated aromatase activity in
the expanded adipose tissue, followed by elevated E2 levels
which suppress the HPG axis [3, 4]. Studies however, which
examined the role of aromatase and/or elevated E2 levels in
obesity, reported conflicting results [23–25]. In males, this
is one of the few studies evaluating aromatase expression in
adipose tissue. Differences in SAT aromatase expression
could not be established between obese men (with or
without type 2 diabetes) and normal-weight men. Further-
more, we could not determine significant results concerning
visceral adipose tissue (VAT) aromatase expression (data
not shown), though SAT aromatase expression only was
used for remaining analysis considering the generally
known higher expression of aromatase in subcutaneous
versus visceral adipocytes [26]. It has previously been
suggested that SAT aromatase expression was associated
with generalized obesity as described by BMI, though Wake
et al. [24] could not find any association between SAT
aromatase and abdominal obesity with which obese men are
mostly characterized with. Some studies have reported data
that counteract with the increased aromatase activity hy-
pothesis. Firstly, Dhindsa et al. [7] reported lower E2 levels,
measured with LC–MS/MS, excluding down-regulation by
Table 2 Associations between sex steroids, aromatase, and metabolic parameters
Parameter Testosterone P value Free testosterone P value Ratio T/E2 P value N
SAT aromatase -0.095 0.600 0.027 0.879 -0.343 0.047 36
LH 0.187 0.104 0.061 0.597 0.112 0.326 82
FSH 0.216 0.064 0.088 0.452 0.173 0.136 82
SHBG 0.694 <0.001 0.383 0.001 0.604 <0.001 82
E2 0.211 0.064 0.214 0.056 -0.308 0.005 82
Free E2 0.054 0.637 0.162 0.151 -0.463 <0.001 82
TG -0.390 <0.001 -0.242 0.033 -0.388 <0.001 82
HOMA-IR -0.444 <0.001 -0.286 0.013 -0.606 <0.001 82
SAT cell size -0.619 <0.001 -0.599 <0.001 -0.648 <0.001 50
Significant P values were indicated in bold
Data are Pearson correlation coefficients (r) adjusted for age. In case of non-Gaussian distribution, variables were log-transformed. LH
luteinizing hormone, E2 estradiol, TG triglycerides, HOMA-IR homeostasis model of assessment for insulin resistance, SAT subcutaneous adipose
tissue
Fig. 2 The relationship between triglycerides and serum testosterone levels (n = 23; a) as well as inverse associations between free testosterone
and subcutaneous adipose tissue (SAT) cell size (n = 11; b) in obese men without type 2 diabetes
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elevated E2 of the HPG axis as the main cause for low T
levels in men with type 2 diabetes. Similar findings have
been reported by Tajar et al. [27] who used LC–MS/MS to
determine E2 as well. Finally, obese males have been de-
scribed to have lower SHBG levels, which also counteracts
with the increased aromatase activity hypothesis resulting
in elevated E2 levels since E2 is known to normally sti-
mulate SHBG production [28].
In the present study, we found, apart from an inverse
correlation between (free) T and SAT cell size in univariate
analyses, an inverse association of (free) T levels with TG
and insulin sensitivity (HOMA-IR). Inverse associations
between T levels and TG are consistent with the findings of
previous studies [29, 30]. Elevated circulating TG levels
have been suggested to be an indicator of metabolic
derangement, associated with both glucose intolerance and
increased amounts of VAT [31–33]. The inverse link be-
tween sex steroids and lipids has been described previ-
ously, suggesting a protective role of T and E2 for the
cardiovascular system [34]. Pitteloud et al. reported an
inverse association between human chorionic gonadotropin
(HCG)-induced T secretion by Leydig cells and insulin
sensitivity (measured by hyperinsulinemic euglycemic
clamp) among men with various degrees of glucose toler-
ance. Thus, Leydig cell function is suggested to be altered
in insulin-resistant men, resulting in decreased T secretion
[35]. Another study reported a diminished T response to
HCG in obese men, which correlated with baseline leptin
levels [36]. Furthermore, Sertoli cell function was also
suggested to be impaired in obese insulin-resistant men,
since two Sertoli cell markers, inhibin B and anti-Mu¨llerian
hormone, were found to be lower in obese versus control men
Table 3 Multivariate linear regression model of variables sig-
nificantly associated with total and free testosterone levels as well as
testosterone-to-estradiol ratio (ratio T/E2) as dependent variables
Variable b SE (b) 95 % CI P value
Total testosterone
Obesity -0.153 0.194 -0.546; 0.240 0.435
DM2 -0.617 0.220 -1.061; -0.173 0.008
Age -0.171 0.118 -0.410; 0.068 0.157
Triglycerides -0.054 0.106 -0.269; 0.160 0.610
HOMA-IR -0.015 0.168 -0.354; 0.324 0.929
SAT cell size -0.324 0.153 -0.633; -0.015 0.040
Free testosterone
Obesity 0.049 0.218 -0.391; 0.489 0.822
DM2 -0.239 0.246 -0.735; 0.258 0.337
Age -0.472 0.132 -0.740; -0.205 0.001
Triglycerides 0.043 0.119 -0.197; 0.282 0.722
HOMA-IR -0.077 0.188 -0.457; 0.302 0.683
SAT cell size -0.446 0.171 -0.791; -0.100 0.013
Ratio T/E2
Obesity -0.183 0.274 -0.772; 0.357 0.455
DM2 -0.519 0.323 -1.271; 0.061 0.073
Age 0.089 0.211 -0.325; 0.543 0.610
Triglycerides -0.158 0.143 -0.437; 0.153 0.330
HOMA-IR 0.116 0.302 -0.493; 0.750 0.673
SAT cell size -0.391 0.218 -0.897; 0.002 0.051
SAT aromatase -0.167 0.184 -0.565; 0.192 0.319
Significant P values were indicated in bold
All b coefficients were standardized. N = 50
Obesity and DM2 are binary variables (yes/no). DM2 type 2 diabetes,
HOMA-IR homeostasis model of assessment for insulin resistance,
SAT subcutaneous adipose tissue, SE standard error, CI confidence
interval
Table 4 Subject characteristics
and sex steroid levels before and
after bariatric surgery
Data are mean ± SD or median
(1st–3rd quartile) in case of non-
Gaussian distribution. P values
were determined using a paired
student t test. Non-Gaussian
distributed variables were log-
transformed
Pre-bariatric
surgery (N = 14)
Post-bariatric
surgery (N = 14)
P value
Clinical and biochemical characteristics
Age (years) 51 ± 12 53 ± 12 \0.001
BMI (kg/m2) 45 ± 8 34 ± 8 \0.001
Fat (%) 45 ± 9 36 ± 12 0.009
Triglycerides (mmol/L) 1.55 ± 0.79 1.09 ± 0.46 0.067
Glucose (mmol/L) 6.47 ± 1.69 5.35 ± 0.74 0.051
Insulin (pmol/L) 122.0 [99.7–211.7] 61.1 [49.9–121.3] 0.001
HOMA-IR 3.3 [2.1–4.2] 1.1 [0.9–2.3] 0.002
Sex steroids
Testosterone (nmol/L) 8.99 ± 4.70 14.62 ± 6.65 0.004
Free testosterone (pmol/L) 189.6 ± 110.5 229.0 ± 116.8 0.157
Estradiol (pmol/L) 70.4 ± 32.1 68.8 ± 25.9 0.848
Free estradiol (pmol/L) 1.33 ± 0.52 1.11 ± 0.44 0.117
SHBG (nmol/L) 27.9 [17.0–36.0] 52.4 [39.6–59.1] \0.001
LH (IU/L) 5.2 [3.0–9.3] 5.8 [2.7–12.6] 0.832
FSH (IU/L) 5.7 [5.0–12.0] 7.4 [5.7–18.4] \0.001
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[37]. The inverse correlation between (free) T, adipocyte cell
size, and HOMA-IR as well as circulating TG in this study
also supports the findings of Pitteloud et al. [35]. On multi-
variate regression analysis, however, SAT cell size remained
the only metabolic parameter that was independently related
to (free) T. Adipocyte cell size has been recognized for many
years as an important parameter in the pathogenesis of
metabolic derangement. Enlarged subcutaneous adipocytes
have been shown to predict type 2 diabetes in a prospective
cohort, independent from clamp-measured insulin sensi-
tivity [38, 39]. It has been shown that insulin-sensitive
though severely obese individuals had a smaller adipocyte
size compared to an equally obese but insulin-resistant group
matched for age, sex, and body fat, suggesting that
mechanisms beyond obesity per se determine the patho-
logical metabolic consequences in obesity [40]. Further-
more, adipocyte cell size has been associated with low-grade
systemic inflammation and macrophage accumulation in
adipose tissue [22, 41]. Our data emphasize the importance
of enlarged SAT cell size and related metabolic changes as a
potential determinant of low T levels in obese men. How-
ever, these findings derive from a cross-sectional study,
limiting conclusive statements on causality.
Our results suggest a direct negative impact of adipo-
cytes, but not IR, on free and total T levels in obese men.
The influence of adipokines, which are regulatory products
of adipose tissue, on reproductive hormones and function
has been repeatedly reported [42–44]. For instance, high
adiponectin levels (typical of normal weight) have recently
been found to regulate Leydig cell steroidogenesis and T
secretion, through the transcriptional regulation of
steroidogenic genes [44]. Expanded adipose tissue is
known to differentially secrete its adipokines, leading to
the release of more pro-inflammatory and less anti-in-
flammatory adipokines in case of obesity. A potential ex-
planation of low (free) T levels could thus be a pro-
inflammatory status in testes secondary to a deregulated
adipokine secretion pattern, as enlarged adipocytes have
been related to a systemic inflammatory state [41, 45].
Some inflammatory mediators, such as the adipokines
TNF-a and leptin, have been shown to negatively influence
HCG-induced T secretion directly from Leydig cells as
well as to disturb Sertoli cell function [35, 42, 43]. Espe-
cially, leptin has been indicated as an important mediator in
the development of reduced androgens in male obesity, as
both influences on the HPG axis and direct testicular ef-
fects were reported by in vitro and in vivo studies [36, 46–
48]. A recent study reported the suppression of HCG-in-
duced T secretion in primary Leydig cells after the addition
of chemerin, a novel adipokine of which elevated levels
have been associated with both obesity and diabetes in
humans [49]. In addition, inflammatory mediators have
also been shown to suppress the HPG axis [50, 51]. The
latter could explain the assumed disturbances in HPG axis,
since primary testes injury normally is accompanied by an
up-regulated gonadotropin release which cannot be
demonstrated in our study cohort. Vermeulen et al. as well
as Giagulli et al. have indicated these alterations in feed-
back regulation of gonadotropins by determining LH pulse
amplitudes in obese men [4, 52].
Finally, bariatric surgery normalized BMI, TG, HOMA-
IR, T, SHBG, and FSH values in the prospective part of our
study. Our findings are consistent with previously reported
data, which found improved BMI and T levels in men after
bariatric surgery together with a restored sexual function
and fertility. In accordance with previous studies, we found
no changes in LH levels before and after surgery. Despite
the use of the dialysis method, we found no changes in free
T levels after GBS, in contrast to studies that used less
precise methods such as calculated free T from total T [15,
53, 54]. This may suggest that a change in SHBG is mainly
responsible for the increase in T, instead of recovery of the
initial causative factors. Another explanation is the limited
number of patients willing to participate in the follow-up
part of the study, which could affect the detection of small
changes. Longitudinal studies on a larger scale are needed
to confirm these results. Recently, when bariatric surgery in
hypogonadal subjects was compared to eugonadal men
however, increase in (free) T levels after surgery had only
been observed in hypogonadal men in combination with a
more pronounced reduction in waist circumference (a
marker of abdominal adiposity of these men). Furthermore,
this study showed lower E2 levels at baseline in hy-
pogonadal versus eugonadal obese men, also minimizing
its role as a determinant of T levels in obese men [54].
The present study has the benefit of LC–MS/MS meth-
ods to determine T levels compared to previous commer-
cial radioimmunoassay kits, leading to more reliable
results, though larger studies are needed to confirm the
findings. Another limitation of this study is the lack of
information on adipose tissue aromatase activity in addi-
tion to the expression analysis, because SAT samples were
frozen or fixated.
In conclusion, low T levels in obese men inversely as-
sociate with SAT cell size, HOMA-IR, and TG levels and
not with adipose tissue aromatase expression, suggesting
obesity-related metabolic disturbances to be more important
for explaining the T levels in obese men. Further research
should be directed at primary T secretion failure of the testis.
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